Skip to content
As one of the first U.S. businesses disrupted by the coronavirus, Apple Inc. (NASDAQ: AAPL) seemed to be a model of superior survival techniques. Now, Apple is approaching future catalysts from a position of strength, according to Wedbush.The Apple Analyst Daniel Ives maintained an Outperform rating on Apple and raised the price target from $335 to $350.The Apple Thesis For the most part, Apple has remained unshaken by COVID-19, according to Wedbush.Its global demand and supply chain have weathered the storm. Yet the lengthening of global lockdowns and the impending economic fallout are expected to delay the company's recovery, in the research firm's view. "To this point, we have continued to encourage investors to use this near-term uncertainty as an opportunity to buy the stock for the other side of the dark valley," Ives said in a Tuesday note. (See his track record here.)The analyst said he sees "Teflon-like" strength in...
Yahoo Finance’s Brian Sozzi and Heidi Chung break down the market action for Apple. ...
Representing work truck fleets of all sizes around the U.S., fleet managers share funding and outsourcing processes. ...
The healthcare sector took its place among the winners this year, rising 11%, compared to the S&P 500’s 9% drop. The bottom-line for investors? Wall Street’s focus is on the healthcare space, locking in on biotechs in particular. However, before making hasty decisions, it should be noted that these stocks are notoriously risky, with their shares prone to explosive movements on account of only a few key catalysts like updates on clinical studies or regulatory approvals. The good news is that a favorable outcome can drive massive share price appreciation. However, the bad news is that the opposite holds true.Understanding the volatile nature of the industry itself, we used TipRanks database to pinpoint exciting biotech plays that won’t break the bank. We found three trading for less than $3 per share that are not only Buy-rated, but also boast colossal long-term growth prospects, with upside potential of at least 200%. vTv...
Yahoo Finance’s Brian Sozzi and Heidi Chung break down the market action for Tesla after CEO Elon Musk resumed production, despite local authority orders....
Market forces rained on the parade of Vuzix Corporation (NASDAQ:VUZI) shareholders today, when the analysts downgraded......
(Bloomberg) -- Billionaire Anil Agarwal is exploring a potential deal to take Indian commodities giant Vedanta Ltd. private, according to people familiar with the matter.The tycoon is speaking with advisers about the possibility of buying out minority shareholders of the Mumbai-listed company, the people said, asking not to be identified because the information is private. While talks are advanced, a deal could still be delayed or fall apart, the people said.Vedanta shares have fallen more than 40% this year, giving the company a market value of about $4.4 billion. Companies controlled by Agarwal and his family own 50.1% of Vedanta, according to exchange filings in March. Representatives for Agarwal and Vedanta didn’t immediately respond to requests for comment.Agarwal’s Volcan Investments Ltd. has in the past taken his London-listed Vedanta Resources Ltd. private as the entrepreneur sought to simplify the corporate structure of his resources group. He had said at that time...
